Cover Story
Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”